Drugs / CAR-T cell infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07695012 | Jun 2026 → Dec 2027 expected | precursor B-cell acute lymphoblastic leukemia | Dr. Zaineb Akram | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T cell infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07695012 ↗ |
| Action | Deplete | “inducing direct cytotoxicity” NCT07695012 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T-cell (CAR-T) therapy involves ex vivo genetic modification of autologous T cells” NCT07695012 ↗ |
| Route | Intravenous | “Administration: Single intravenous infusion following lymphodepleting chemotherapy” NCT07695012 ↗ |
| Target | CD19 | “Single-chain variable fragment (scFv) targeting human CD19” NCT07695012 ↗ |